Sunesis Pharmaceuticals — Viracta Therapeutics — Corporate Update (August 2021)
34 slides from Sunesis Pharmaceuticals's corporate update, Aug 12, 2021
Slide 1: Viracta Therapeutics, Inc. August 2021
Viracta Therapeutics, Inc. August 2021 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management of Viracta Therape
Slide 3: Viracta Therapeutics: Introduction
Viracta Therapeutics: Introduction Viracta is a precision oncology company focused on the treatment of virus-associated malignancies Strong balance sheet Approximately $122.7 million in cash as of June 30, 2021, with projected runway into 2024 Expansion of clinical pipeline into EBV+ solid tumors in
Slide 4: Epstein-Barr Virus (EBV): A High Global Cancer Priority
Epstein-Barr Virus (EBV): A High Global Cancer Priority EBV infects cells Latent infection established in subset of cells Latently infected cells evade immune detection and become malignant EBV: A Herpes family virus affecting a majority of the population Persists as a life-long latent infection, re
Slide 5: Viracta's Oral "Kick and Kill" Approach Selectively Targets EBV+ Cancer Cells
EBV is latent in cancer cells and viral kinase genes are silenced epigenetically. Valganciclovir, an antiviral prodrug of ganciclovir (GCV), is inactive in the absence of the expression of viral protein kinase Nanatinostat selectively and potently induces expression of EBV kinase genes which can act
Slide 6: Pipeline: Innovative approaches to virus-associated and other cancers
INDICATION PRECLINICAL EARLY-STAGE CLINICAL LATE-STAGE CLINICAL REGULATORY SUBMISSION Nanatinostat + Valganciclovir EBV+ Lymphoma Nanatinostat + Valganciclovir EBV+ Solid Tumors Other Virus-associated Malignancies (CMV, HHV6, HPV) VRx-510* PDK-1 Inhibitor Oncology – multiple undisclosed indications
Slide 7: EBV+ Lymphoma Program
viracta EBV* Lymphoma Program
Slide 8: EBV: Prognostic Significance and Detection
EBV: Prognostic Significance and Detection EBV encoded RNA in situ hybridization (EBER-ISH): Validated assay Standardized and easy to administer Directly detects EBV in cancerous cells Dark blue: EBV genome DLBCL Plasmablastic NK/T EBV positivity correlates with shortened survival in DLBCL, PTCL and
Slide 9: VT3996-201 Phase 1b/2 Trial of Nstat/VGCV in R/R EBV+ Lymphoma
CYCLE 2 28 Days VT3996-201 Phase 1b/2 Trial of Nstat/VGCV in R/R EBV+ Lymphoma Endpoints: Response rate (ORR by PET-CT; Lugano 2014), response duration, safety, clinical benefit rate (CBR) Open-label, dose escalation/expansion study of oral Nstat+VGCV combination in patients with recurrent EBV+ lymp
Slide 10: Promising Activity in Heavily Pre-treated, Refractory EBV+ Lymphomas
Promising Activity in Heavily Pre-treated, Refractory EBV+ Lymphomas Subtype Enrolled (n) Evaluable (n) B-NHL 10 (22%) 9 DLBCL 7 CR (2), PR (2), SD (2) Other B Cell 3 PD (3) T-NHL 15 (33%) 10 ENKTL 6 CR, PR (3), PD PTCL, NOS 3 CR, PR AITL 5 CR (2) CTCL 1 PD Immunodeficiency-associated 13 (28%) 10 PT
Slide 11: Response Duration for All Evaluable Patients (N=35)
Response Duration for All Evaluable Patients (N=35) Time, months B-NHL T/NK-NHL IA-LPD Hodgkin 2 4 6 8 10 12 14 16 18 Withdrawn for autoSCT Withdrawn for autoSCT Withdrawn for CAR-T cell therapy ENKTL T-NHL By lymphoma subtype As of October 27, 2020
Slide 12: RP2D has a Favorable Safety Profile
Phase 1b (n=25) Phase 2 (n=21) All G3/4 All G3/4 Thrombocytopenia 13 (52%) 8 (32%) 5 (24%) 3 (14%) Nausea 10 (40%) 0 7 (33%) 2 (10%) Neutropenia 9 (36%) 7 (28%) 6 (29%) 6 (29%) Anemia 9 (36%) 5 (23%) 5 (24%) 5 (24%) Lymphopenia 6 (24%) 5 (23%) 4 (19%) 3 (14%) Leukopenia 5 (20%) 3 (12%) 4 (19%) 2 (10
Slide 13: VT3996-201 Phase 1b/2 Study: Key Findings
VT3996-201 Phase 1b/2 Study: Key Findings Nstat/VGCV at the RP2D has promising activity and is well tolerated in refractory EBV+ lymphomas ORR: 80% in EBV+ T cell lymphomas (n=10) 44% in EBV+ B cell lymphomas (n=9) (including 4 of 6 responses in DLBCL patients) Multiple complete responses observed i
Slide 14: Case Studies
SMILE (L-asparaginase-containing) plus radiotherapy (1st Line), ASCT (2nd line); refractory to last therapy Relapses post- SMILE regimen generally have a poor prognosis, with a median overall survival of 4-6 months Patient was being considered for palliative care Partial remission 1.9 months after s
Slide 15: Key FDA Regulatory Milestones Achieved
Key FDA Regulatory Milestones Achieved End of Phase 2 Meeting (November 2020) Obtained alignment on the design of Viracta’s Phase 2 pivotal study; a single arm basket study with an adaptive design in patients with relapsed/ refractory EBV+ lymphomas. Fast Track Designation (November 2019) For the tr
Slide 16: ORR/DoR from Single Arm Studies in R/R Lymphoma Receiving Accelerated Approval
ORR/DoR from Single Arm Studies in R/R Lymphoma Receiving Accelerated Approval Nstat/VGCV comparison to lymphoma drugs receiving accelerated approval ORR and DoR for Nstat/VGCV in EBV+ lymphoma compare favorably with other accelerated approvals in various R/R lymphomas Objective Response Rate Median
Slide 17: NAVAL-1 Pivotal Phase EBV+ Lymphoma Trial
NAVAL-1 Pivotal Phase 2 EBV+ Lymphoma Trial Global, multicenter basket study with an adaptive Simon 2-stage design Patient population: Relapsed/refractory EBV+ lymphoma with ≥ 2 prior therapies and no curative options (n=140) Extranodal NK/T cell lymphoma ≥1 prior therapy Primary objective: To evalu
Slide 18: Encouraging Feedback from Physician/KOL and Payor Primary Market Research
Encouraging Feedback from Physician/KOL and Payor Primary Market Research for Viracta’s Differentiated Approach in EBV+ Lymphoma KOL/Payer TPP Reaction: Unmet Need 10%-15% of all lymphomas are EBV-associated in US ~10,000 EBV+ Lymphoma/year in US ~3,000 EBV+ DLBCL ~1,200 EBV+ PTCL ~500 EBV + ENKTL ~
Slide 19: EBV+ Solid Tumor Program
viracta EBV* Solid Tumor Program
Slide 20: Preclinical Proof of Concept for Nstat & VGCV Combination in Solid Tumors
Preclinical Proof of Concept for Nstat & VGCV Combination in Solid Tumors Annual incidence of nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC): ~218,000 (global) and ~5,500 (N. America) High unmet need exists, especially for R/R disease Efficacy of combination approach was initially reporte
Slide 21: Induction by Nstat of EBV Protein Kinase in Tumor Cells and Tissue Uptake
Induction by Nstat of EBV Protein Kinase in Tumor Cells and Tissue Uptake of Nstat in Xenograft tumors in Mice Phase 1b/2 study in EBV+ solid tumors planned to start in H2 2021 Induction by Nstat of EBV Protein Kinase RNA in SNU-719 EBV+ Gastric Carcinoma Cell Line High Tumor Uptake of Nstat in a Mu
Slide 22: VT3996-301 Phase 1b/2 Study in EBV+ Solid Tumors
VT3996-301 Phase 1b/2 Study in EBV+ Solid Tumors Study will evaluate the safety and preliminary activity of nanatinostat & VGCV alone and in combination with pembrolizumab Patient population: N = up to 88 patients Phase 1b: Dose selection: EBV+ recurrent/metastatic nasopharyngeal carcinoma (RM-NPC)
Slide 23: EBV+ Malignancy Estimated Addressable Market
EBV+ Malignancy Estimated Addressable Market for Lymphoma, Nasopharyngeal Cancer (NPC) and Gastric Carcinoma (GC) Annual Incidence Source:; Kahn,G, et al, BMJ 10: 1136, 2020; Epidemiology of EBV-associated Cancers in the US by Tessellon, July 2020 Global Market by Region (est.) N. America:17,000 Eur
Slide 24: Key Recent and Upcoming Milestones
Key Recent and Upcoming Milestones Initiation of NAVAL-1, a global pivotal clinical trial for R/R EBV+ lymphomas ✓ EXPECTED IN H1 2021 (Completed) Clearance of EBV+ solid tumor IND EXPECTED IN MID-2021 (Completed) EXPECTED IN H2 2021 Updated data from the Phase 1b/2 VT3996-201 study in R/R EBV+ lymp
Slide 25: Leadership Team
Leadership Team Ayman Elguindy, PhD Chief Scientific Officer Michael Mueller VP, Legal Affairs & General Counsel Hybritech Ivor Royston, MD President and Chief Executive Officer Lisa Rojkjaer, MD Chief Medical Officer Cheryl Madsen Senior VP, Regulatory Affairs Shelly Vandertie VP, Finance Daniel Ch
Slide 26: Viracta Therapeutics: Investment Thesis
Viracta Therapeutics: Investment Thesis Contact Us: info@viracta.com Focused on addressing an unmet medical need and significant global market with a novel targeted therapeutic approach that represents a new MOA for the treatment EBV-associated cancers Promising efficacy and safety from early clinic
Slide 27: Appendix
viracta Appendix
Slide 28: Viracta Therapeutics, Inc. - Formation & Financing History
T cell lymphoma ODD EOP2 Meeting w FDA Series E Financing ($40M) Announced Merger with Sunesis and $65M Concurrent Financing Closed merger; NASDAQ: VIRX Initiated EBV+ lymphoma pivotal study (Q2 2021) Initiate EBV+ solid tumor Ph1b/2 (expected H2 2021) Acquired CHR-3996 (now Nanatinostat) from Chrom
Slide 29: Board of Directors and Scientific Advisory Board
Board of Directors and Scientific Advisory Board Scientific and Clinical Advisors Roger J. Pomerantz, MD Chairman of the Board President, Chief Executive Officer & Chairman of the Board, ContraFect Corporation Ivor Royston, MD President and Chief Executive Officer, Viracta Tom Darcy Chairman of the
Slide 30: EBV Pleiotropic Roles in Oncogenesis
EBV Pleiotropic Roles in Oncogenesis LMP-1 Inhibits p53; upregulates bcl2 Upregulates NF-kB EBNA3 Inhibits RB & p53 Upregulates c-myc EBNA2 BHRF1 is bcl2 homologue inhibit apoptosis BCRF1 mimics IL-10 suppress T cells Induction of PDL1 suppress T cells McLaughlin-Drubin, M.E. & Munger K; Biochem Bio
Slide 31: Limitations of Current Treatment Paradigm
Subtypes 1st Line SoC 2nd Line Options Limitations of Current Treatment Paradigm DLBCL R-CHOP TL or Salvage ChemoRx + ASCT Outlook for refractory patients is bleak CAR-T for 3rd line Peripheral T-cell Lymphoma/AITL CHO(E)P or BV+CHP for CD30+ HDACi, BV, or Salvage ChemoRx High unmet need with lack o
Slide 32: Median duration of response (n=15)
Median duration of response (n=15) Time, months Event-free probability Median duration of response: 10.4 months As of October 27, 2020
Slide 33: Viracta's Synthetic Lethality Approach is Protected by a Strong IP Portfolio
Viracta’s Synthetic Lethality Approach is Protected by a Strong IP Portfolio Granted patents provide protection into at least 2040 2005 2010 2020 2025 2030 2035 2040 2045 2000 Expiration January 2027 (Including Patent Term Adjustment) Expiration May 2040 2015 Additional intellectual property (IP) pr
Slide 34: Viral Infections and Cancer
Viral Infections and Cancer 15-20% of Cancers Worldwide Contain Latent Viral Genomes Viral Genomes Oncogenic Proteins Viral Infection & Cancer HPV HCV Liver cancer Cervical, oropharyngeal cancer E6, E7 Core, N53, NS5A MCV Merkel cell carcinoma LT, sT KSHV Kaposi’s sarcoma, etc. LANA, viRF, vCyclin H
Viracta Therapeutics — Corporate Update (August 2021) on 6ix